Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 12, Issue 3, Pages 279-288Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2016.1118347
Keywords
Beclomethasone dipropionate hydrofluoroalkane; intranasal corticosteroids; nasal aerosol; nasal spray; allergic rhinitis; inflammation; asthma
Categories
Ask authors/readers for more resources
Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone layer have been developed for the treatment of AR. The use of these devices might improve patients' adherence to treatment, avoiding some of the most common side effects associated with aqueous formulations. This review provides the most recent evidence for the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane nasal aerosol in the treatment of allergic rhinitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available